- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
IMRIS Completes First Two Cases For Pediatric Horseshoe Headrest
IMRIS Inc. (TSX:IM,NASDAQ:IMRS) completed its first two cases using MR-safe headrest designed specifically for intraoperative imaging with VISIUS® intraoperative MRI (iMRI).
IMRIS Inc. (TSX:IM,NASDAQ:IMRS) completed its first two cases using MR-safe headrest designed specifically for intraoperative imaging with VISIUS® intraoperative MRI (iMRI). The IMRIS horseshoe headrest is the world’s first MR-safe and CT-compatible horseshoe headrest on the market, used for neonatal to adult patients during neurosurgical procedures requiring intraoperative imaging in the VISIUS® Surgical Theatre.
As quoted in the press release:
“The IMRIS horseshoe headrest worked well for providing the ideal prone positioning during this procedure,” said Dr. Frederick Boop, Chairman of the Department of Neurosurgery and Co-director of Le Bonheur’s Neuroscience Institute who performed the first case of a tumor surgery on a five- year-old child. “In the past we would not have had an iMRI option for this child and now the tumor is completely gone. We have now advanced our treatment to a group of kids for whom it will really make a difference. Even our youngest and most fragile patients can benefit from intraoperative MR, which would not have been possible otherwise.”
Click here to read the IMRIS Inc. (TSX:IM) press release
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.